Literature DB >> 16135525

In vitro selection of mutants of Streptococcus pneumoniae resistant to macrolides and linezolid: relationship with susceptibility to penicillin G or macrolides.

H Carsenti-Dellamonica1, M Galimand, F Vandenbos, C Pradier, P M Roger, B Dunais, M Sabah, G Mancini, P Dellamonica.   

Abstract

OBJECTIVES: To evaluate the rate of acquisition of resistance to linezolid and macrolides in Streptococcus pneumoniae isolates with different levels of susceptibility to penicillin and erythromycin.
MATERIALS AND METHODS: Thirty strains of S. pneumoniae were tested by serial passages in subinhibitory concentrations of each antibiotic by the spiral method. The four copies of the 23S rRNA rrl gene of parent strains and linezolid-resistant mutants were amplified and sequenced.
RESULTS: The rate of acquisition of macrolide resistance did not differ when C-14 and C-16 macrolides were tested. Resistance to linezolid in strains susceptible to penicillin and erythromycin was difficult to produce. For mutants with low-level resistance to linezolid the cut-off value of the MIC was between 6 and 8 mg/L depending on the strain. All linezolid-resistant mutants displayed a mutation in 2-4 copies of the 23S rRNA rrl gene, mainly the G2576U mutation (27/30) with an additional C2610U mutation observed in certain mutants. Two new mutations were also noted, namely C2612A and C2571G. In three linezolid-resistant mutants no mutation was identified within the studied domain, suggesting another mechanism of resistance.
CONCLUSIONS: Linezolid resistance in pneumococcal strains susceptible to penicillin and macrolides was more difficult to obtain than with macrolides. Increased resistance to these agents may therefore influence the clinical use of linezolid.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16135525     DOI: 10.1093/jac/dki301

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  8 in total

Review 1.  Resistance to linezolid caused by modifications at its binding site on the ribosome.

Authors:  Katherine S Long; Birte Vester
Journal:  Antimicrob Agents Chemother       Date:  2011-12-05       Impact factor: 5.191

2.  Mutations in 23S rRNA at the peptidyl transferase center and their relationship to linezolid binding and cross-resistance.

Authors:  Katherine S Long; Christian Munck; Theis M B Andersen; Maria A Schaub; Sven N Hobbie; Erik C Böttger; Birte Vester
Journal:  Antimicrob Agents Chemother       Date:  2010-08-09       Impact factor: 5.191

3.  In vitro-selected linezolid-resistant Mycobacterium tuberculosis mutants.

Authors:  Doris Hillemann; Sabine Rüsch-Gerdes; Elvira Richter
Journal:  Antimicrob Agents Chemother       Date:  2007-12-10       Impact factor: 5.191

4.  Genome sequencing of linezolid-resistant Streptococcus pneumoniae mutants reveals novel mechanisms of resistance.

Authors:  Jie Feng; Andréanne Lupien; Hélène Gingras; Jessica Wasserscheid; Ken Dewar; Danielle Légaré; Marc Ouellette
Journal:  Genome Res       Date:  2009-04-06       Impact factor: 9.043

5.  Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700).

Authors:  Jeffrey B Locke; Mark Hilgers; Karen Joy Shaw
Journal:  Antimicrob Agents Chemother       Date:  2009-09-14       Impact factor: 5.191

6.  Mutations in ribosomal protein L3 are associated with oxazolidinone resistance in staphylococci of clinical origin.

Authors:  Jeffrey B Locke; Mark Hilgers; Karen Joy Shaw
Journal:  Antimicrob Agents Chemother       Date:  2009-10-05       Impact factor: 5.191

7.  Erythromycin for prokinesis: imprudent prescribing?

Authors:  Martino Dall'Antonia; Mark Wilks; Pietro G Coen; Susan Bragman; Michael R Millar
Journal:  Crit Care       Date:  2006-02       Impact factor: 9.097

Review 8.  Linezolid Resistance in Staphylococci.

Authors:  Stefania Stefani; Dafne Bongiorno; Gino Mongelli; Floriana Campanile
Journal:  Pharmaceuticals (Basel)       Date:  2010-06-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.